<DOC>
	<DOCNO>NCT00247676</DOCNO>
	<brief_summary>The study consist two part . In Part 1 study start enrol 38 patient 25 patient total 63 eligible patient . If study give good result expand total 160 patient . SU011248 administer orally daily 4 week follow 2-week rest start dose 50 mg [ milligrams ] provision dose reduction base tolerability . All patient receive repeat cycle SU011248 disease progression , occurrence unacceptable toxicity , withdrawal criterion meet . After discontinuation treatment , patient follow order collect information antineoplastic therapy survival</brief_summary>
	<brief_title>An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically confirm diagnosis hepatocellular carcinoma Patients must present disease amenable curative surgery ( i.e . either hepatectomy , liver transplant ) . Evidence measurable disease radiographic technique Adequate organ function . Prior treatment systemic treatment liver cancer Presence clinically relevant ascites Severe hemorrhage &lt; 4 week start study treatment . Diagnosis second malignancy within last 3 year History know brain metastasis , spinal cord compression , carcinomatous meningitis Known human immunodeficiency virus ( HIV ) Serious acute chronic illness Current treatment another clinical trial Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Liver neoplasm , sunitinib , Phase 2</keyword>
</DOC>